These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 24740463

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
    Modi Y, Shaaban H, Gauchan D, Maroules M.
    J Oncol Pharm Pract; 2015 Feb; 21(1):74-5. PubMed ID: 25063763
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
    Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL.
    Blood; 2007 Jun 01; 109(11):4739-41. PubMed ID: 17327409
    [Abstract] [Full Text] [Related]

  • 8. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R.
    Lancet Haematol; 2017 Mar 01; 4(3):e127-e136. PubMed ID: 28162984
    [Abstract] [Full Text] [Related]

  • 9. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
    McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH, TPL102357 Study Group.
    N Engl J Med; 2007 Nov 29; 357(22):2227-36. PubMed ID: 18046027
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review.
    Wang X, Liu X, Wang L, Wang JY, Li A.
    Blood Coagul Fibrinolysis; 2019 Mar 29; 30(2):71-74. PubMed ID: 30720490
    [Abstract] [Full Text] [Related]

  • 14. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience.
    Yaman Y, Elli M, Şahin Ş, Özdilli K, Bilgen H, Bayram N, Nepesov S, Anak S.
    Pediatr Transplant; 2021 Aug 29; 25(5):e13962. PubMed ID: 33452850
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK.
    Lancet Haematol; 2015 Aug 29; 2(8):e315-25. PubMed ID: 26688484
    [Abstract] [Full Text] [Related]

  • 17. Eltrombopag in thrombocytopenia.
    Zimmer J, Hentges F, Andrès E.
    N Engl J Med; 2008 Mar 06; 358(10):1072; author reply 1072-3. PubMed ID: 18326076
    [No Abstract] [Full Text] [Related]

  • 18. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia.
    Reid R, Bennett JM, Becker M, Chen Y, Milner L, Phillips GL, Liesveld J.
    Am J Hematol; 2012 Jul 06; 87(7):743-5. PubMed ID: 22573520
    [Abstract] [Full Text] [Related]

  • 19. [Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia].
    Horikoshi A, Tsukuda J, Abe R, Fujiwara N, Ito E, Takaku T.
    Rinsho Ketsueki; 2016 May 06; 57(5):638-41. PubMed ID: 27263792
    [Abstract] [Full Text] [Related]

  • 20. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.
    Taylor A, Westwood JP, Laskou F, McGuckin S, Scully M.
    Br J Haematol; 2017 May 06; 177(3):475-480. PubMed ID: 28295201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.